# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Guggenheim analyst Paul Jeng assumes Immunocore Holdings (NASDAQ:IMCR) with a Neutral rating.
Immunocore Hldgs (NASDAQ:IMCR) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0....
https://www.bloomberg.com/news/articles/2025-08-04/south-africa-gates-step-in-after-us-defunds-hiv-research
HC Wainwright & Co. analyst Patrick Trucchio reiterates Immunocore Holdings (NASDAQ:IMCR) with a Buy and maintains $100 ...
Oppenheimer analyst Jeff Jones maintains Immunocore Holdings (NASDAQ:IMCR) with a Outperform and raises the price target fro...
Immunocore Hldgs (NASDAQ:IMCR) reported quarterly earnings of $0.10 per share which beat the analyst consensus estimate of $(0....
JP Morgan analyst Jessica Fye maintains Immunocore Holdings (NASDAQ:IMCR) with a Overweight and lowers the price target from...